Remove analyst-stock-ratings
article thumbnail

The Rise of “Sell-Side Activism”: Why It’s Happening and How to Respond

Harvard Corporate Governance

They may be more surprised to hear about an emerging trend: an increase in so-called “sell-side activism” in which a company’s sell-side analysts advocate directly for change. These letters go beyond a traditional “sell” rating, instead advocating for specific, sometimes wholesale, changes at the company. more…)

article thumbnail

Uber Could Be Brewing A Plan To Enter Grocery Sector: Instacart Stock Spikes On Acquisition Whispers

Benzinga

Uber Technologies Inc (NYSE: UBER ) is reportedly considering the acquisition of grocery delivery company Instacart, according to a recent analyst report. The news has significantly impacted Instacart’s (NASDAQ: CART ) stock, which experienced a notable surge. increase in the stock price, which reached $25.48.

EBITDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

VIZIO Faces Analyst Downgrades Amid Walmart Acquisition, Impact On Roku

Benzinga

Shares of VIZIO Holding (NYSE: VZIO ) closed lower on Wednesday amid a series of downgrades from Wall Street analysts. JPMorgan downgraded the stock to Neutral, while raising their price target to $11.50 Craig-Hallum downgraded Vizio stock to Hold Roth MKM downgraded the stock to Neutral, lowering their price target to $11.50

52
article thumbnail

3 Catalysts To Drive Growth At Cisco: $28B Splunk Deal Offers 'Great Synergies,' Analyst Says

Benzinga

The stock has underperformed the market over the last 12 months mainly due to weakness in Networking. The Cisco Systems Analyst: Tal Liani upgraded the rating for Cisco Systems from Neutral to Buy, while raising the price target from $55 to $60.

article thumbnail

ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note

Benzinga

The ImmunoGen Analyst : Joseph Catanzaro downgraded the rating for ImmunoGen from Overweight to Neutral, while raising the price target from $24 to $31. Check out other analyst stock ratings. The deal, which is expected to close in mid-2024, represents a “great price” for ImmunoGen, at $31.26

59
article thumbnail

Analyst Favors Exxon Mobil Deal, But Downgrades Pioneer Natural Resources: Here's Why

Benzinga

BMO Capital Markets analyst Phillip Jungwirth downgraded Pioneer Natural Resources Co (NYSE: PXD ) to Market Perform from Outperform rating. The analyst reduced the rating on its all-stock merger with Exxon Mobil Corp (NYSE: XOM ) for $59.5 billion, or $253 per share.

article thumbnail

Zoom Valuation Reaching 'Washed-Out Levels,' Over 30% Upside Despite M&A Caution

Benzinga

After zooming through the pandemic, Zoom Video Communications (NASDAQ: ZM ) stock declined by 15% over the past year, and 13.6% The Zoom Video Analyst: JPMorgan analyst Mark R. Murphy rates the stock Neutral with a price target of $83. so far this year. It is set to report fourth-quarter earnings on Feb.